Background: The aim of this clinical trial was to establish a proof of concept that the adjunctive use of systemic azithromycin (AZM) in conjunction with mechanical debridement has an increased benefit in reducing soft tissue inflammation in the treatment of peri-implantitis. Methods: In a randomized, double-blind, clinical trial, the treatment group (nine patients) received AZM as well as mechanical debridement in a single course of treatment, whereas the control group (eight patients) received a placebo and mechanical debridement. The primary outcome variables studied were bleeding on probing, suppuration, pocket probing depth and gingival recession. The secondary variables studied were gingival index, plaque index, microbiological and interleukin-1b status. The observation period was 6 months. Results: Over the 6 months' observation period, the treatment patients showed a consistently greater reduction of gingival inflammation and an improvement in soft tissue healing than the control patients. Conclusions: The adjunctive use of a single course of systemic azithromycin can assist in the control of peri-implant mucositis in the treatment of peri-implantitis.
INTRODUCTION
As a group of distinct clinical conditions, peri-implant diseases (PID) are impacting on contemporary dental practice in a significant way. 1 The early stage of PID (peri-implant mucositis) is characterized by soft tissue inflammation, the loss of gingival seal around implant abutment/restoration complex, with or without frank exudation from the gingival sulci around implants. The later stage of PID (peri-implantitis) is characterized by the additional bone loss around the implant body as evidenced from radiographic imaging and/or clinical examination. 2, 3 If unchecked, the progression of peri-implant mucositis to peri-implantitis will have serious consequences for the survival of the affected implant/restoration.
There is general agreement that PID have a microbial origin. A recent systematic review by Mombelli et al. 4 described the microbiota in PID. Several studies have also demonstrated the presence of higher proportions of other microbiological species such as Fusobacterium spp., Campylobacter spp., Staphylococci spp. and Peptostreptococci spp. 5, 6 The methods of management of PID (peri-implantitis and peri-implant mucositis) are many and varied. [7] [8] [9] [10] Currently, there is no universally agreed best practise protocol to manage peri-implant infection, inflammation or tissue loss. Several protocols have described the non-surgical treatment of peri-implantitis which involved the mechanical debridement of the implant surface alone or combined with antiseptics or antibiotics. 11 Although there are reports on the efficacy of systemic azithromycin (AZM) use in conjunction with mechanical debridement for the treatment of periodontal disease, [12] [13] [14] there is only one report of AZM use in the treatment of peri-implantitis and periimplant mucositis. 15 Studies have shown that following oral dosing, AZM is extensively distributed throughout the tissues in both animal models 16, 17 and in humans. [18] [19] [20] One of the important 
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The official journal of the Australian Dental Association pharmacodynamic features of this drug is that high tissue concentrations is sustained over a long period of time even after the serum concentration is reduced to very low levels. This suggests that the killing and clearing of bacteria in the local tissue (of a disease site) can still be active and effective long after the drug has been cleared in circulation.
The aim of the current study was to evaluate the changes in relevant clinically measures of peri-implantitis in patients after mechanical debridement with or without AZM. It also aimed to provide new information on the microbiological and immunological effects of AZM dosing in the treatment of PID.
METHODS

Study design and protocol
This study was a double-blind, prospective randomized placebo-controlled clinical trial for an observational period of 6 months (~180 days). The purpose of the trial was to evaluate the clinical and microbiological outcomes, levels of interleukin (IL)-1b and changes in levels of AZM within the peri-implant crevicular fluid (PICF) following the non-surgical debridement with or without adjunctive use of systemic AZM in patients diagnosed with peri-implantitis. Notification to conduct a clinical trial involving drugs under the Clinical Trial Notification scheme, pursuant to Schedule 5A of Regulation 12 of the Therapeutics Goods Regulation, was lodged and approved by the Therapeutics Goods Administration (Australian Government) under trial number 2013/0330.
Ethical approval was obtained from the Western Sydney Local Health District Human Ethics Committee (HREC2012/11/4. 6(3569) AU RED HREC/12/ WMEAD/273) and a written consent form was signed by each patient. Consecutive patients referred to the Westmead Centre for Oral Health (Westmead, Sydney, NSW, Australia) for the management of periimplantitis were assessed for eligibility for participation in this study. A total of 17 from 25 patients were matched with the inclusion and exclusion criteria and recruited into the study. There was no restriction on the brand/type of implants or the restorative design or configuration. Inclusion criteria were over 18 years old, absence of uncontrolled systemic disease, presence of one or more single implants accessible to periimplant probing and presenting with peri-implantitis in at least one implant, defined as having a pocket probing depth (PPD) of 5 mm or more with bleeding on probing (BOP) with or without suppuration, and radiographic bone loss of more than 2 mm after abutment connection. Exclusion criteria were untreated periodontal disease, smoking defined as more than 5 cigarettes/day, plaque index above 25%, use of antibiotics in the past 6 months, history of allergy to AZM or other macrolide antibiotics, patients with known cardiac arrhythmias, pregnant and lactating women, and implants inaccessible to peri-implant probing.
The primary outcome variables studied were those clinical features that form the clinical assessment of gingival inflammation which included BOP and suppuration, PPD and gingival margin retraction (recession in mm). The secondary outcome variables studied were gingival index (GI), plaque index (PI) and microbiological and cytokine results. Subjects who fulfilled our eligibility criteria were invited to participate in the study and informed written consent was obtained. Patients were randomized to receive AZM or a placebo according to a computer-generated table (Excel 2010 Microsoft â software; Microsoft, Redmond, WA, USA). The table was generated by a person not connected to the study and blinded to the treatment allocation. Probing depths and BOP were carried out at six sites per implant using the HuFriedy PCP-UNC 15 periodontal probe (Hu-Friedy, Chicago, IL, USA). Plaque samples were obtained prior to peri-implant probing. The PI was measured dichotomously at the six sites per implant. Full mouth plaque scores were noted using disclosing solution (Plaque Disclose Gel; Professional Dental Supplies, Bayswater, Vic., Australia) and expressed as average of index (0-3) at all six sites. BOP was assessed dichotomously using a pressure sensitivity of 0.2 N (Hawe Click-Probe; Kerr Hawe, Bioggio, Switzerland) at the six sites around the implant. GI was also recorded using the Silness-L€ oe index. Recession was assessed using a Hu-Friedy PCP-UNC 15 periodontal probe. Considering that the implant-abutment margin was often subgingival, the occlusal table of the restoration was used as a reference point. Changes in gingival margin levels were recorded as a recession. Intraoral periapical radiographs of the implants studied were taken on day 0 and day 180. Radiographic measurements of bone loss (mm) were taken from the shoulder of the implant to the level of bone-implant contact on periapical radiographs.
The treatment procedure was provided by one operator (LG) who remained blinded to the allocation of the treatment group. AZM or placebo was packaged in a concealed container labelled with a patient number only and issued by the Clinical Trials Pharmacist at the Westmead Hospital Pharmacy. At baseline, patients were given appropriate oral hygiene advice which consisted of tooth brushing technique of the entire mouth with focus on the affected implant as well as interproximal cleaning techniques with the use of interdental brushes (TePe Munhygienprodukter, Malm€ o, Sweden). Mechanical treatment was only performed at baseline (day 0) and patients in both groups received mechanical debridement. Following mechanical treatment, patients were issued AZM 500 mg or placebo consisting of 1 capsule per day for a consecutive 3 days. Patients returned at days 3, 7, 21, 90 and 180 for follow-up microbiological and immunological sampling. Any adverse effects were recorded on a patient record sheet. Any patients showing signs of deterioration including increasing bleeding, suppuration, pain or discomfort were to be withdrawn from the study and offered surgical peri-implant treatment.
Sample collection and laboratory analyses
Peri-implant crevicular fluid samples at relevant sites were collected with sterile endodontic paper points (ISO 055; Dentsply Maillefer, Montigny Le Bretonneux, France) at the prescheduled time points and stored at À180°C until assay. The total viable aerobic and anaerobic microbiological counts expressed as colony-forming units (CFU)/mL were obtained by conventional culturing methods on agar plates supplemented with growth nutrient as required. Aggregatibacter actinomycetemcomitans was cultured according to Tsuzukibashi et al.'s methods. 21 The variability of species of bacteria associated at the periimplant interface was analysed according to microbial complexes as outlined by Socransky et al. 22 The detection frequency of these complexes was then analysed at baseline and compared between treatment groups. This provided a convenient way to profile the microorganisms at the peri-implant interface with an emphasis on known pathogenic species. Anaerobic cultures were carried out on anaerobic agar plates and incubated anaerobically in specialized jars using the AnaeroPack system. Aerobic cultures were incubated in an atmosphere of 5% CO 2 to facilitate growth of aerobic species at 37°C for 5 days. The AZM level in PICF at various time points was assayed using the Driscoll method (Carbonnelle et al., 2011) . 23 Briefly, Bacillus subtilis was grown according to standard methods. Serial dilution of PICF was used to determine the concentration that bacterial killing had occurred. The enzyme-linked immunoassay (ELISA) for IL-1b was conducted at the Centre for Immunology and Allergy Research, Westmead Millennium Institute by an examiner (AK) and a senior laboratory manager. The pro-inflammatory cytokine IL-1b concentrations in the PICF samples were assessed using a commercially available ELISA kit (eBioscience, San Diego, CA USA) as per the manufacturer's instructions.
Statistical analyses
All statistical analyses were performed using IBM SPSS version 21 (IBM, Armonk, NY, USA) and a significance level of P < 0.05. Owing to the variation between patients in all clinical measures at day 0, 'change scores' were calculated by deducting a patient's score at each of the time points from their baseline score at day 0. If a patient's change score was negative, this would indicate a reduction in the outcome variable and, alternatively, if the change score was positive, this would indicate an increase in the clinical indicator being measured.
Baseline characteristics of age (independent samples t-test), gender and patients with a history of periodontitis (Mann-Whitney U-test) were analysed to determine if treatment groups were significantly different from one another. BOP, suppuration, GI and PI scores were analysed using Mann-Whitney U-test at each data collection time point to determine significant differences between groups. Recession and PPD were analysed using a mixed model ANOVA with Bonferroni corrections on paired comparisons to explore differences between the groups across the data collection time points. Chi-squared tests were applied to determine if the frequency detection of the various microbial complexes were statistically significant between treatment groups at baseline. Microbiological and immunological counts taken per patient were pooled to a mean value. The independent samples t-test was applied to this data to determine if mean counts per treatment group were statistically different from one another at the six different time points.
RESULTS
Patient information
In Table 1 , the characteristics of the study population are presented. There were nine patients in the drug treatment (AZM) group and eight in the control group, making a total of 17 patients studied. The L Gershenfeld et al.
mean age, gender distribution, history of periodontal disease, total number of implants in each of the groups, and the mean age of the implants per group and overall are also indicated. No statistically significant difference (P > 0.05) was found when comparing the drug and placebo groups on any of the variables measured pretreatment (Table 1) . One patient (in the AZM group) was lost to follow up at day 180 due to relocation and the data for that time point was not included in the analysis.
Clinical measures
The effects of AZM use in conjunction with non-surgical debridement in the treatment of peri-implantitis are shown in Fig. 1 . The clinical parameters measured were BOP (Fig. 1a) and suppuration (Fig. 1b) over the study period of 180 days. Figure 1(a) shows that when comparing mean percentage of the groups that exhibited BOP at various time points, the AZM group demonstrated a greater reduction after treatment compared with the placebo group. Paired comparisons using Bonferroni corrections showed significant differences between the groups at day 7 (P = 0.01), day 21 (P = 0.02), day 180 (P = 0.01) and approaching significance at day 90 (P = 0.06).
With the exception of the day 0 time point, the placebo group consistently showed a higher mean percentage of BOP than the AZM group of patients. In Fig. 1(b) , the AZM group again shows a consistently greater reduction in suppuration than the placebo group when expressed in percentage suppuration. The difference shown was less marked (in contrast to the BOP results in Fig. 1a ) and at no time was the difference between groups statistically significant. To assess the soft tissue response to AZM treatment, PPD and gingival margin recession measurements were recorded. The results are shown in Fig. 2 . In Fig. 2(a) , the results of the PPD changes are shown. Both groups show a reduction in PPD as a result of treatment, but the AZM group consistently showed greater reduction than the placebo group with significant differences at day 21 (P = 0.02), day 90 (P = 0.02) and day 180 (P = 0.05). In Fig. 2(b) , recession changes are less pronounced between groups. The placebo group showed a slight increase in gingival recession, but the AZM group showed a slight gain. The difference between groups was not significant. When comparing clinical indices, GI and PI, the results between groups were less clear. Figure 3(a) shows that the AZM group had a lower mean GI score than the placebo group across most time points with the differences statistically significant at day 7 (P = 0.05), day 21 (P = 0.01) and day 180 (P = 0.04). In Fig. 3(b) , both groups showed a dramatic reduction in PI immediately after treatment and thereafter rebound to a stable level with no significant differences between groups at any data collection time point. Table 2 shows the change in bone level recorded before and after therapy (day 0 and day 180) in each patient. Change of bone level was calculated by comparing the pre-and post-treatment measurements. There was no statistical significance when comparing the group means. Figure 4 is a composite with three panels showing the results of microbiological and IL-1b assays. The top two panels show the mean for aerobic and anaerobic bacteria counts at six time points for the two treatment groups (AZM and placebo). Differences between groups approached significance at day 90 in favour of the AZM group; however, no statistically significant differences were observed between the treatment groups at any of the times points observed.
Radiographic results
Microbiological and IL-1b data
The third panel shows the mean for IL-1b levels between the two treatment groups expressed as pg/mL. Both groups demonstrated a trend for mean reduction in IL-1b levels after treatment over time that was sustained throughout the study. No statistically significant differences were observed between treatment groups at any of the time points observed. Table 3 shows the percentage frequency of viable bacterial complexes found by culture at baseline. If at least one species from a complex was detected, this was tabulated accordingly. Across all patients and between groups, the orange complex species were found in the highest frequency (94.1%). Bacteria of the purple, green and yellow complexes were also Positive change indicates an increase in bone whereas a negative change indicates a loss of bone. AZM = azithromycin; SD = standard deviation. L Gershenfeld et al.
Bacterial complexes at baseline
found at varying frequencies whilst the red complex bacteria were found at the lowest frequency (17.6%). There were no significant differences between treatment groups observed at baseline.
Concentration of AZM
After the plates were incubated for 24 h at 37°C, specimens with a bacterial zone of inhibition were noted as a positive result. No positive results (zones of inhibition) were observed in the samples across any of the time points. These samples equated to a 1/20 dilution factor from the original sample.
DISCUSSION
This study examined the additive effect of systemic use of AZM in conjunction with mechanical debridement in the treatment of peri-implantitis. The change in soft tissue inflammation following treatment was measured by BOP and suppuration, changes in PPD and recession, as well as GI and PI. All parameters showed an improvement up to day 21. Thereafter, the 'non-inflamed' status continued for the entire observation period (180 days). This result was consistent with the findings of previous reports which examined the effect on the use of AZM in the treatment of periodontitis. 12, 14, [24] [25] [26] In contrast, other reports have found AZM to be ineffective when used in conjunction with mechanical debridement in the treatment of severe or aggressive periodontitis. [27] [28] [29] The reason for a divergence of results of clinical trials with apparently similar study protocols is unclear. The lack of a clear description of the peri-implantitis lesions and the surrounding conditions could be an unaccounted for variable that needs to be addressed.
The microbiological data presented in this paper are consistent with those reported by Haffajee's group. 30, 31 Interestingly, when we analysed the presence/absence of bacterial complexes, 22 the orange complex, not the red complex was the most dominant group present. These data are consistent with the findings of a recent report by the Lang group 32 where they found general similarities of bacterial types between peri-implant sites versus periodontitis sites, as well as healthy control sites. However, Fusobacterium nucleatum, a confirmed periodontopathic organism was predominantly found in periodontitis sites and not peri-implantitis sites. It is worth noting that the overwhelming species detected was Staphylococcus aureus which is not usually associated with gingival inflammation. Perhaps there are subtle differences between the microbiota in periodontitis and peri-implantitis or peri-implant mucositis that have not been adequately studied to date. Further research will no doubt advance our understanding of the disease process of the gingiva and periodontium.
Interleukin-1b has been used as a convenient marker for gingival inflammation. 33 When we assayed for IL-1b in the PICF, we noted an initial and dramatic reduction in both groups at day 7 and then remained 'depressed' for the remaining observation period of the study. However, the difference between groups was not statistically significant. This laboratory observation once again mirrored the clinical observation that there was a notable improvement in the gingival inflammation following treatment (in both groups) and that gingival health was maintained throughout the observation period, with the AZM group showing greater improvement than the control group. Our data on IL-1b levels were also consistent with those presented in a review by Bartold et al. 34 We are therefore confident that our laboratory data were supportive of our clinical findings.
In this current study, we were unable to detect AZM in the PICF. Our results were consistently less than 10 lg/mL which was below the detection limit of our assay system. In contrast, using a local delivery system for AZM, and a detection technology utilizing high-pressure liquid chromatography, Pradeep et al. were able to titrate out AZM in the PICF over a 4-week period. 35 Despite our lack of success in detecting AZM locally in PICF, our clinical result in resolving soft tissue inflammation was evident. We speculate that it may not be necessary to achieve a high concentration of AZM locally in order to achieve good clinical results. Other groups have reviewed the pharmacological effects of AZM on local immune cells 34, 36 and suggested that good clinical response to AZM treatment may be attributed to the involvement of an upregulated immune mechanism by AZM.
In a similar study to this study, Hallstrom et al. reported that adjunctive use of systemic AZM did not show any difference compared with the control group in the treatment of peri-implantitis 15 Their protocol was almost identical to ours with the exception of the dosing protocol. Hallstrom et al. used 500 mg AZM on day 1 and followed by 3 days of 250 mg. The current study, as with most reports on AZM use in periodontitis, used 500 mg/day over a consecutive 3 days. It is unclear if the dosing difference can bring about differences in clinical outcome. Future studies will be required to answer this question.
In comparison with the clinical data obtained, we noted that the timing of clinical improvement in patients after AZM dosing appeared to mirror the changes in the microbial and IL-1b levels. We are therefore encouraged by the findings of this study, and propose that a larger scale population study may add weight to our results. In this current study, we did not study the stand-alone effect of AZM use (monotherapy) in the treatment of peri-implant mucositis. Neither did we examine the effect of AZM use in the repair of bony lesions (peri-implantitis). Future studies with a different design will be needed to answer these important questions.
CONCLUSIONS
In conclusion, this study found that the adjunctive use of AZM is beneficial in the management of periimplantitis, particularly in the resolution of soft tissue inflammation.
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